Spero Therapeutics shares are trading lower after the company announced its Phase 2a proof-of-concept study of SPR720 did not meet its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
Spero Therapeutics' shares declined following the announcement that their Phase 2a study of SPR720 failed to meet its primary endpoint.
October 30, 2024 | 10:49 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Spero Therapeutics' stock is negatively impacted after the failure of their Phase 2a study of SPR720 to meet its primary endpoint.
The failure of a clinical trial to meet its primary endpoint is a significant setback for a biotech company, often leading to a decline in stock price due to reduced investor confidence in the product's future potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100